Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 62.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 21,637 shares of the medical equipment provider’s stock after selling 35,343 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Hologic were worth $1,763,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Seven Eight Capital LP raised its stake in shares of Hologic by 35.3% during the first quarter. Seven Eight Capital LP now owns 4,169 shares of the medical equipment provider’s stock valued at $325,000 after purchasing an additional 1,088 shares in the last quarter. UniSuper Management Pty Ltd raised its position in shares of Hologic by 435.7% during the 1st quarter. UniSuper Management Pty Ltd now owns 14,845 shares of the medical equipment provider’s stock worth $1,157,000 after buying an additional 12,074 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Hologic by 8.0% in the 1st quarter. Bessemer Group Inc. now owns 10,892 shares of the medical equipment provider’s stock worth $848,000 after acquiring an additional 809 shares during the period. Shell Asset Management Co. boosted its holdings in shares of Hologic by 68.6% in the first quarter. Shell Asset Management Co. now owns 10,517 shares of the medical equipment provider’s stock valued at $820,000 after acquiring an additional 4,279 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its stake in shares of Hologic by 72.6% during the first quarter. Canada Pension Plan Investment Board now owns 453,913 shares of the medical equipment provider’s stock valued at $35,387,000 after acquiring an additional 190,881 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 0.7 %

HOLX stock opened at $78.04 on Thursday. The business’s 50-day simple moving average is $80.52 and its 200 day simple moving average is $78.30. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a market cap of $18.13 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the business earned $0.89 earnings per share. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HOLX shares. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. UBS Group lifted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and dropped their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. increased their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.